FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023241301> ?p ?o ?g. }

• W2023241301 endingPage "244" @default.
• W2023241301 startingPage "241" @default.
• W2023241301 abstract "Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is still associated with a dismal outcome. Combination therapy with everolimus (EVL) and vascular endothelial growth factor inhibitor sorafenib (SORA) is based on the role of both b-Raf and mammalian target of rapamycin/protein kinase B pathways in the pathogenesis of HCC and is being investigated in clinical practice.This was a single-center retrospective analysis on LT recipients with unresectable HCC recurrence and undergoing combination therapy with EVL and SORA. Patients were included if they were switched to EVL+SORA at any time after surgery. Primary endpoint was overall survival (OS) after both LT and recurrence, and response to treatment based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) in the intention-to-treat (ITT) population. Secondary analysis was safety of combination therapy with EVL and SORA in the population of patients who received ≥1 dose of the study drug.Seven patients (100% male; median age 53 years [interquartile range (IQR) 9 years]) were considered for analysis. HCC recurrence was diagnosed at a median (IQR) interval since LT of 9 (126) months, and patients were administered EVL+SORA at a median interval since LT of 11 (126) months. Baseline immunosuppression was with tacrolimus (TAC) in 2 patients (28.6%), cyclosporine (CsA) in 2 (28.6%), and EVL monotherapy in 3 (42.8%). At a median (IQR) follow-up of 6.5 (14) months, 5 patients (71.4%) were alive, 4 of them (57.1%) with tumor progression according to the mRECIST criteria. Median (IQR) time to progression was 3.5 (12) months. Two patients died at a median (IQR) follow-up of 5 (1) months owing to tumor progression in 1 patient (14.3%) and sepsis in the other (14.3%). EVL monotherapy was achieved in 6 patients (85.7%), whereas 1patient (14.3%) could not withdraw from calcineurin inhibitor owing to acute rejection. Treatment complications were: hand-foot syndrome in 5 patients (71.4%), hypertension in 1 (14.3%), alopecia in 1 (14.3%), hypothyroidism in 1 (14.3%), diarrhea in 2 (28.6%), pruritus in 1 (14.3%), abdominal pain in 1 (14.3%), rash in 1 (14.3%), asthenia in 3 (42.8%), anorexia in 3 (42.8%), and hoarseness in 2 (28.6%). Adverse events led to temporary SORA discontinuation in 2 patients (28.6%) and to SORA dose reduction in 3 (42.8%).Treatment of HCC recurrence after LT with a combination regimen of EVL+ SORA is challenging because of SORA-related complications. Longer follow-up periods and larger series are needed to better capture the impact of such combination treatment on tumor progression and patient survival." @default.
• W2023241301 created "2016-06-24" @default.
• W2023241301 creator A5002183143 @default.
• W2023241301 creator A5009939421 @default.
• W2023241301 creator A5010761253 @default.
• W2023241301 creator A5011265052 @default.
• W2023241301 creator A5033663489 @default.
• W2023241301 creator A5035992792 @default.
• W2023241301 creator A5036079877 @default.
• W2023241301 creator A5043647966 @default.
• W2023241301 creator A5053299889 @default.
• W2023241301 creator A5065733742 @default.
• W2023241301 creator A5068616432 @default.
• W2023241301 creator A5070360122 @default.
• W2023241301 creator A5073492849 @default.
• W2023241301 creator A5090594438 @default.
• W2023241301 date "2014-01-01" @default.
• W2023241301 modified "2023-10-16" @default.
• W2023241301 title "Efficacy and Safety of Combination Therapy With Everolimus and Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation" @default.
• W2023241301 cites W1972036735 @default.
• W2023241301 cites W1973557719 @default.
• W2023241301 cites W1979833056 @default.
• W2023241301 cites W1983684477 @default.
• W2023241301 cites W2047834354 @default.
• W2023241301 cites W2048999265 @default.
• W2023241301 cites W2062548816 @default.
• W2023241301 cites W2079586464 @default.
• W2023241301 cites W2079649533 @default.
• W2023241301 doi "https://doi.org/10.1016/j.transproceed.2013.10.035" @default.
• W2023241301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24507059" @default.
• W2023241301 hasPublicationYear "2014" @default.
• W2023241301 type Work @default.
• W2023241301 sameAs 2023241301 @default.
• W2023241301 citedByCount "39" @default.
• W2023241301 countsByYear W20232413012014 @default.
• W2023241301 countsByYear W20232413012015 @default.
• W2023241301 countsByYear W20232413012016 @default.
• W2023241301 countsByYear W20232413012017 @default.
• W2023241301 countsByYear W20232413012018 @default.
• W2023241301 countsByYear W20232413012019 @default.
• W2023241301 countsByYear W20232413012020 @default.
• W2023241301 countsByYear W20232413012021 @default.
• W2023241301 countsByYear W20232413012022 @default.
• W2023241301 countsByYear W20232413012023 @default.
• W2023241301 crossrefType "journal-article" @default.
• W2023241301 hasAuthorship W2023241301A5002183143 @default.
• W2023241301 hasAuthorship W2023241301A5009939421 @default.
• W2023241301 hasAuthorship W2023241301A5010761253 @default.
• W2023241301 hasAuthorship W2023241301A5011265052 @default.
• W2023241301 hasAuthorship W2023241301A5033663489 @default.
• W2023241301 hasAuthorship W2023241301A5035992792 @default.
• W2023241301 hasAuthorship W2023241301A5036079877 @default.
• W2023241301 hasAuthorship W2023241301A5043647966 @default.
• W2023241301 hasAuthorship W2023241301A5053299889 @default.
• W2023241301 hasAuthorship W2023241301A5065733742 @default.
• W2023241301 hasAuthorship W2023241301A5068616432 @default.
• W2023241301 hasAuthorship W2023241301A5070360122 @default.
• W2023241301 hasAuthorship W2023241301A5073492849 @default.
• W2023241301 hasAuthorship W2023241301A5090594438 @default.
• W2023241301 hasConcept C119060515 @default.
• W2023241301 hasConcept C126322002 @default.
• W2023241301 hasConcept C141071460 @default.
• W2023241301 hasConcept C143998085 @default.
• W2023241301 hasConcept C203092338 @default.
• W2023241301 hasConcept C2776694085 @default.
• W2023241301 hasConcept C2776999253 @default.
• W2023241301 hasConcept C2778019345 @default.
• W2023241301 hasConcept C2778695046 @default.
• W2023241301 hasConcept C2779609443 @default.
• W2023241301 hasConcept C2779699572 @default.
• W2023241301 hasConcept C2779984678 @default.
• W2023241301 hasConcept C2780252810 @default.
• W2023241301 hasConcept C2908647359 @default.
• W2023241301 hasConcept C2909675724 @default.
• W2023241301 hasConcept C2911091166 @default.
• W2023241301 hasConcept C31760486 @default.
• W2023241301 hasConcept C535046627 @default.
• W2023241301 hasConcept C71924100 @default.
• W2023241301 hasConcept C90924648 @default.
• W2023241301 hasConcept C99454951 @default.
• W2023241301 hasConceptScore W2023241301C119060515 @default.
• W2023241301 hasConceptScore W2023241301C126322002 @default.
• W2023241301 hasConceptScore W2023241301C141071460 @default.
• W2023241301 hasConceptScore W2023241301C143998085 @default.
• W2023241301 hasConceptScore W2023241301C203092338 @default.
• W2023241301 hasConceptScore W2023241301C2776694085 @default.
• W2023241301 hasConceptScore W2023241301C2776999253 @default.
• W2023241301 hasConceptScore W2023241301C2778019345 @default.
• W2023241301 hasConceptScore W2023241301C2778695046 @default.
• W2023241301 hasConceptScore W2023241301C2779609443 @default.
• W2023241301 hasConceptScore W2023241301C2779699572 @default.
• W2023241301 hasConceptScore W2023241301C2779984678 @default.
• W2023241301 hasConceptScore W2023241301C2780252810 @default.
• W2023241301 hasConceptScore W2023241301C2908647359 @default.
• W2023241301 hasConceptScore W2023241301C2909675724 @default.
• W2023241301 hasConceptScore W2023241301C2911091166 @default.
• W2023241301 hasConceptScore W2023241301C31760486 @default.
• W2023241301 hasConceptScore W2023241301C535046627 @default.

• next